Evidence map›Paper›PMID 26755550›Full record

Observational studyJournal of the American Heart Association2016

Galectin-3 Is Elevated and Associated With Adverse Outcomes in Patients With Single-Ventricle Fontan Circulation.

Alexander R Opotowsky, Fernando Baraona, Justin Owumi, Brittani Loukas, Michael N Singh, Anne Marie Valente, Fred Wu, Susan Cheng, Gruschen Veldtman, Eric B Rimm and 1 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Article
  3. Evolving Proteomic Biomarkers in Children with Congenital Heart Defects.Journal of cardiovascular development and disease · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. A Scoping Review of Galectin-3 as a Biomarker of Cardiovascular Diseases in Pediatric Populations.International journal of environmental research and public health · 2022
    Article
  13. Article
  14. Fontan-Associated Dyslipidemia.Journal of the American Heart Association · 2021
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Biomarker profile in stable Fontan patients.International journal of cardiology · 2020
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Alexander R OpotowskyDepartment of Medicine, Brigham and Women's Hospital, Boston, MA (A.R.O., M.N.S., A.M.V., F.W., S.C., M.J.L.) Department of Cardiology, Boston Children's Hospital, Boston, MA (A.R.O., J.O., B.L., M.N.S., A.M.V., F.W., M.J.L.).
Fernando BaraonaDivisión de Enfermedades Cardiovasculares, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile (F.B.).
Justin OwumiDepartment of Cardiology, Boston Children's Hospital, Boston, MA (A.R.O., J.O., B.L., M.N.S., A.M.V., F.W., M.J.L.).
Brittani LoukasDepartment of Cardiology, Boston Children's Hospital, Boston, MA (A.R.O., J.O., B.L., M.N.S., A.M.V., F.W., M.J.L.).
Michael N SinghDepartment of Medicine, Brigham and Women's Hospital, Boston, MA (A.R.O., M.N.S., A.M.V., F.W., S.C., M.J.L.) Department of Cardiology, Boston Children's Hospital, Boston, MA (A.R.O., J.O., B.L., M.N.S., A.M.V., F.W., M.J.L.).
Anne Marie ValenteDepartment of Medicine, Brigham and Women's Hospital, Boston, MA (A.R.O., M.N.S., A.M.V., F.W., S.C., M.J.L.) Department of Cardiology, Boston Children's Hospital, Boston, MA (A.R.O., J.O., B.L., M.N.S., A.M.V., F.W., M.J.L.).
Fred WuDepartment of Medicine, Brigham and Women's Hospital, Boston, MA (A.R.O., M.N.S., A.M.V., F.W., S.C., M.J.L.) Department of Cardiology, Boston Children's Hospital, Boston, MA (A.R.O., J.O., B.L., M.N.S., A.M.V., F.W., M.J.L.).
Susan ChengDepartment of Medicine, Brigham and Women's Hospital, Boston, MA (A.R.O., M.N.S., A.M.V., F.W., S.C., M.J.L.) Framingham Heart Study, Framingham, MA (S.C.).
Gruschen VeldtmanCincinnati Children's Hospital Heart Institute, Cincinnati, OH (G.V.).
Eric B RimmChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA (E.B.R.) Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, MA (E.B.R.).
Michael J LandzbergDepartment of Medicine, Brigham and Women's Hospital, Boston, MA (A.R.O., M.N.S., A.M.V., F.W., S.C., M.J.L.) Department of Cardiology, Boston Children's Hospital, Boston, MA (A.R.O., J.O., B.L., M.N.S., A.M.V., F.W., M.J.L.).

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
Myocardial and Arterial Aging: Spectrum, Correlates, and PrognosisR00HL107642 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CHENG, SUSAN · 2014 to 2016
$747k
NCATS NIH HHS UL1 TR001102NHLBI NIH HHS R00 HL107642NHLBI NIH HHS R00HL107642
6 · The paper itself

Abstract

backgroundGalectin-3 may play a role in cardiac and noncardiac fibrosis, and elevated circulating levels of this protein predict adverse outcomes in patients with heart failure who do not have congenital heart disease. We investigated galectin-3 in adults with single-ventricle Fontan circulation, patients who are prone to premature clinical deterioration in the context of extensive multiorgan fibrosis. METHODS AND

resultsWe measured plasma galectin-3 concentrations in 70 ambulatory adult Fontan patients and 21 age- and sex-matched control participants. Galectin-3 level was significantly higher in the Fontan group (11.85 ng/mL, interquartile range 9.9 to 15.0 ng/mL) versus the control group (9.4 ng/mL, interquartile range 8.2 to 10.8 ng/mL; P<0.001). Among Fontan patients, galectin-3 was positively correlated with age, uric acid, and high-sensitivity C-reactive protein and negatively correlated with estimated glomerular filtration rate. There was no significant relationship between galectin-3 and oxygen saturation, Fontan type, or ventricular morphology. Over a median follow-up of 461 days, 15 events occurred among the Fontan patients: 12 nonelective hospitalizations (with 2 subsequent deaths) and 3 deaths without prior hospitalization. Patients with elevated galectin-3 (n=19, defined as >2 SD above the control group mean value) had a higher risk of nonelective hospitalization or death (hazard ratio 6.0, 95% CI 2.1 to 16.8, P<0.001). This relationship persisted after individual adjustment for covariates including age, New York Heart Association functional class, C-reactive protein, and estimated glomerular filtration rate and after multivariable adjustment for independently predictive covariates (hazard ratio 9.2, 95% CI 2.4 to 35.2, P=0.001).

conclusionsGalectin-3 concentrations are elevated among adults with a Fontan circulation, and elevated galectin-3 is associated with an increased risk of nonelective cardiovascular hospitalization or death.

Indexed as

AdultBiomarkersBlood ProteinsCase-Control StudiesFemaleFontan ProcedureGalectin 3GalectinsHeart Defects, CongenitalHumansMaleMiddle AgedPatient ReadmissionRisk AssessmentRisk FactorsTime FactorsBiomarkersBlood ProteinsGalectin 3GalectinsLGALS3 protein, humanadult congenital heart diseasebiomarkercongenital heart diseaseFontan proceduregalectin‐3

Identifiers

PMID26755550
PMCPMC4859390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.